Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-006236
Filing Date
2021-05-06
Accepted
2021-05-06 16:18:18
Documents
75
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nbrv-20210331x10q.htm   iXBRL 10-Q 1942121
2 EX-5.1 nbrv-20210331xex5d1.htm EX-5.1 28022
3 EX-10.1 nbrv-20210331xex10d1.htm EX-10.1 76176
4 EX-10.2 nbrv-20210331xex10d2.htm EX-10.2 275275
5 EX-10.3 nbrv-20210331xex10d3.htm EX-10.3 56913
6 EX-10.4 nbrv-20210331xex10d4.htm EX-10.4 45423
7 EX-10.5 nbrv-20210331xex10d5.htm EX-10.5 56676
8 EX-10.6 nbrv-20210331xex10d6.htm EX-10.6 53741
9 EX-31.1 nbrv-20210331xex31d1.htm EX-31.1 10551
10 EX-31.2 nbrv-20210331xex31d2.htm EX-31.2 11267
11 EX-32.1 nbrv-20210331xex32d1.htm EX-32.1 5749
12 EX-32.2 nbrv-20210331xex32d2.htm EX-32.2 6282
13 GRAPHIC nbrv-20210331xex5d1002.jpg GRAPHIC 2726
14 GRAPHIC nbrv-20210331xex5d1001.jpg GRAPHIC 2853
15 GRAPHIC nbrv-20210331xex10d1002.jpg GRAPHIC 5581
  Complete submission text file 0001558370-21-006236.txt   8063932

Data Files

Seq Description Document Type Size
16 EX-101.SCH nbrv-20210331.xsd EX-101.SCH 54413
17 EX-101.CAL nbrv-20210331_cal.xml EX-101.CAL 48095
18 EX-101.DEF nbrv-20210331_def.xml EX-101.DEF 283549
19 EX-101.LAB nbrv-20210331_lab.xml EX-101.LAB 473761
20 EX-101.PRE nbrv-20210331_pre.xml EX-101.PRE 452983
21 EXTRACTED XBRL INSTANCE DOCUMENT nbrv-20210331x10q_htm.xml XML 1132021
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37558 | Film No.: 21898055
SIC: 2834 Pharmaceutical Preparations